In this Vital Health Podcast, Duane Schulthess speaks with Rachel King, the Interim CEO of the Biotechnology Innovation Organization (BIO), who is steering the organization through the increasingly choppy waters of the DC drug pricing debate. With mounting regulatory pressure from all angles towards the global biopharma sector, Washington DC’s BIO sits at the center of the tempest.
Rachel King comes to BIO with a wealth of experience as the former Chair of BIO’s Board of Directors. She has worked as a VC, and was both the co-founder and CEO of GlycoMimetics. She was also a senior VP at Novartis.

In this Vital Health Podcast, Duane Schulthess speaks with Rachel King, the Interim CEO of the Biotechnology Innovation Organization (BIO), who is steering the organization through the increasingly choppy waters of the DC drug pricing debate. With mounting regulatory pressure from all angles towards the global biopharma sector, Washington DC’s BIO sits at the center of the tempest.
<ul>
<li>Rachel King comes to BIO with a wealth of experience as the former Chair of BIO’s Board of Directors. She has worked as a VC, and was both the co-founder and CEO of GlycoMimetics. She was also a senior VP at Novartis.</li>
</ul>

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess, Managing Director of Vital Tran…

Vital Health Podcast

Taking the Helm Mid Drug Pricing Maelstrom

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Melanie Whittington, Managing Director and Head of the Leerink Center for Pharmacoeconomics and Senior Fellow at the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center.

They examine how health economic modeling can more accurately reflect real-world market dynamics, the rising pressure behind IRA and MFN drug pricing, the risks to oncology innovation, the limits of conventional cost-effectiveness frameworks, plus the role of transparency and clearer communication of long-term value in sustaining a healthy innovation ecosystem.

Key Topics
Market Modeling: Hypothetical models versus real-world pricing dynamics, patent cliffs.
Pricing Policy: IRA, MFN, market-based pricing scrutiny, communicating why prices are "worth it".
Innovation Incentives: Private capital risk, oncology small molecules, policy-driven pipeline shifts.
Value Framework Limits: QALY concerns, rule-versus-tool debates, GRACE, broader treatment impacts.
Transparency and Outlook: Net price opacity, PBM negotiations, generics and biosimilars, the next innovation cycle.

Opinions expressed are those of the speakers. The Leerink Center for Pharmacoeconomics is a division of MEDACorp.

In this episode of the Vital Health Podcast, host <a href="https://www.linkedin.com/in/duane-schulthess-66ba39b7/">Duane Schulthess</a> speaks with <a href="https://www.linkedin.com/in/melanie-whittington/">Melanie Whittington</a>, Managing Director and Head of the Leerink Center for Pharmacoeconomics and Senior Fellow at the <a href="https://www.linkedin.com/company/cevr/">Center for the Evaluation of Value and Risk in Health at Tufts Medical Center</a>.
They examine how health economic modeling can more accurately reflect real-world market dynamics, the rising pressure behind IRA and MFN drug pricing, the risks to oncology innovation, the limits of conventional cost-effectiveness frameworks, plus the role of transparency and clearer communication of long-term value in sustaining a healthy innovation ecosystem.
Key Topics
<ul>
<li>Market Modeling: Hypothetical models versus real-world pricing dynamics, patent cliffs.</li>
<li>Pricing Policy: IRA, MFN, market-based pricing scrutiny, communicating why prices are "worth it".</li>
<li>Innovation Incentives: Private capital risk, oncology small molecules, policy-driven pipeline shifts.</li>
<li>Value Framework Limits: QALY concerns, rule-versus-tool debates, GRACE, broader treatment impacts.</li>
<li>Transparency and Outlook: Net price opacity, PBM negotiations, generics and biosimilars, the next innovation cycle.</li>
</ul>
Opinions expressed are those of the speakers. The Leerink Center for Pharmacoeconomics is a division of MEDACorp.

Melanie Whittington: Why Are Drugs So Expensive?

Read our MFN preprint: https://vitaltransformation.com/2026/02/preprint-new-research-the-impact-of-mfn-on-oncology-and-hematology-treatments/

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two Vital Transformation colleagues on biopharma pricing policy, market access, and innovation risk:
Gwen O'Loughlin: Research Partner at Vital Transformation
Harry Bowen: Consulting Economist at Vital Transformation

They discuss what our new MFN pricing modeling suggests about drug viability, how IRA incentives appear to be reshaping oncology and orphan drug development, why Medicare Advantage and commercial coverage can create administrative friction and delays compared with traditional Medicare, how 340B opacity and consolidation affect the value chain, and what these pressures could mean for insurance premiums, investment, and future innovation.

Key Topics:
MFN Modeling: Net present value analysis, benchmark-country pricing, launch viability, and market uncertainty.
Effects of IRA on Trials: Oncology pullback, small-molecule exposure, orphan drug pressure, and suspended trials.
Coverage Friction: Medicare Advantage burden, prior authorization delays, formulary shifts, and referral slowdowns.
340B Transparency: Vertical integration, hospital consolidation, opaque pricing flows, and revenue pressure.
Innovation Outlook: Premium increases, global competition, intellectual property risk, and future access concerns.

Opinions expressed are those of the speakers.

Read our MFN preprint: <a href="https://vitaltransformation.com/2026/02/preprint-new-research-the-impact-of-mfn-on-oncology-and-hematology-treatments/">https://vitaltransformation.com/2026/02/preprint-new-research-the-impact-of-mfn-on-oncology-and-hematology-treatments/</a>
In this episode of the Vital Health Podcast, host <a href="https://www.linkedin.com/in/duane-schulthess-66ba39b7/">Duane Schulthess</a> speaks with two <a href="https://www.linkedin.com/company/vital-transformation/">Vital Transformation</a> colleagues on biopharma pricing policy, market access, and innovation risk:
<ul>
<li><a href="https://www.linkedin.com/in/gwen-o-loughlin-8792003a9/">Gwen O'Loughlin</a>: Research Partner at <a href="https://www.linkedin.com/company/vital-transformation/">Vital Transformation</a></li>
<li><a href="https://www.linkedin.com/in/harry-p-bowen-10761b31/">Harry Bowen</a>: Consulting Economist at <a href="https://www.linkedin.com/company/vital-transformation/">Vital Transformation</a></li>
</ul>
They discuss what our new MFN pricing modeling suggests about drug viability, how IRA incentives appear to be reshaping oncology and orphan drug development, why Medicare Advantage and commercial coverage can create administrative friction and delays compared with traditional Medicare, how 340B opacity and consolidation affect the value chain, and what these pressures could mean for insurance premiums, investment, and future innovation.
Key Topics:
<ul>
<li>MFN Modeling: Net present value analysis, benchmark-country pricing, launch viability, and market uncertainty.</li>
<li>Effects of IRA on Trials:&nbsp;Oncology pullback, small-molecule exposure, orphan drug pressure, and suspended trials.</li>
<li>Coverage Friction: Medicare Advantage burden, prior authorization delays, formulary shifts, and referral slowdowns.</li>
<li>340B Transparency: Vertical integration, hospital consolidation, opaque pricing flows, and revenue pressure.</li>
<li>Innovation Outlook: Premium increases, global competition, intellectual property risk, and future access concerns.</li>
</ul>
Opinions expressed are those of the speakers.

VT's Grumpies and Lady Discuss the U.S. Biotech Policy Landscape

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Tim Scott, President & CEO of Biocom California, a biopharma executive with more than two decades of experience, including spinning out companies from UC San Diego and leading firms acquired by BioMarin and Novartis, to discuss how California’s life sciences ecosystem became a global innovation engine, why the state’s research and venture networks matter, and how policy headwinds such as the Inflation Reduction Act (IRA) and Most Favored Nation (MFN) reference pricing reshape investment, rare disease development, and competition with Europe and China.

Key Topics:


Biocom Origins: Municipal policy roots, industry advocacy, ecosystem evolution across California.


Innovation Network: University and research density, regional clusters, talent, and collaboration effects.


Capital Pathway: NIH and NSF support, SBIR and STTR bridges, venture appetite, and liquidity.


MFN and IRA: Pill penalty incentives, orphan exemption stakes, Medicare exposure, and VC pullback.


Next-Gen Development: AI-enabled discovery, faster trial enrollment, digital twins, and regulator openness.

Opinions expressed are those of the speakers.

In this episode of the Vital Health Podcast, host <a href="https://www.linkedin.com/in/duane-schulthess-66ba39b7/">Duane Schulthess</a> speaks with <a href="https://www.linkedin.com/in/tim-scott-501631/">Tim Scott</a>, President &amp; CEO of&nbsp;<a href="https://www.linkedin.com/company/biocom-california/">Biocom California</a>, a biopharma executive with more than two decades of experience, including spinning out companies from UC San Diego and leading firms acquired by BioMarin and Novartis, to discuss how California&rsquo;s life sciences ecosystem became a global innovation engine, why the state&rsquo;s research and venture networks matter, and how policy headwinds such as the Inflation Reduction Act (IRA) and Most Favored Nation (MFN) reference pricing reshape investment, rare disease development, and competition with Europe and China.
Key Topics:
<ul data-start="642" data-end="1173">
<li data-start="642" data-end="745">
Biocom Origins: Municipal policy roots, industry advocacy, ecosystem evolution across California.
</li>
<li data-start="746" data-end="857">
Innovation Network: University and research density, regional clusters, talent, and collaboration effects.
</li>
<li data-start="858" data-end="956">
Capital Pathway: NIH and NSF support, SBIR and STTR bridges, venture appetite, and liquidity.
</li>
<li data-start="957" data-end="1060">
MFN and IRA: Pill penalty incentives, orphan exemption stakes, Medicare exposure, and VC pullback.
</li>
<li data-start="1061" data-end="1173">
Next-Gen Development: AI-enabled discovery, faster trial enrollment, digital twins, and regulator openness.
</li>
</ul>
Opinions expressed are those of the speakers.

Taking the Helm Mid Drug Pricing Maelstrom

In 1 playlist(s)

Vital Health Podcast

Social links

Follow podcast

Recent clips